Skip to main content
Premium Trial:

Request an Annual Quote

Metabolon Raises Additional $15M in Financing

NEW YORK (GenomeWeb) – Metabolon said today that it has raised an additional $15 million in funding from healthcare equity firm Essex Woodlands.

Essex Woodlands invested an initial $15 million in Metabolon in August.  At the time, the company said it planned to use  the money to develop and commercialize its pipeline of metabolomics technology-based precision medicine products. Metabolon also noted that Essex had the option to increase its investment by an additional $10 million, which would be used to repurchase shares from existing investors. 

Indeed, Metabolon said that the funds from Essex’s follow-on investment have already been used to repurchase and retire certain shares held by existing investors.

Including this latest investment, Metabolon has raised approximately $95 million in funding since it was founded in 2000.

The Scan

CRISPR Screens Reveal Heart Attack-Linked Gene

Researchers in PLOS Genetics have used CRISPR screens to home in on variants associated with coronary artery disease that affect vascular endothelial function.

Meta AI Computer Model Rapidly Predicts Hundreds of Millions of Metagenomic Proteins

Meta AI researchers describe in Science a new large language model that can predict the structures of millions of metagenomic proteins.

Hutch Team Develops Platform for Assessing Impact of SARS-CoV-2 Spike Mutations

The approach described in Cell relies on lentiviral pseudotyping for mutational scanning, which the researchers applied to the SARS-CoV-2 spike protein.

Potential New Therapeutic Target for Rheumatoid Arthritis Discovered

Researchers report in the American Journal of Human Genetics that SNPs implicated in rheumatoid arthritis often regulate the expression of the inflammation-related SPRED2 gene.